Smart-Money SignalDistribution · 21/100— Insiders are net sellers over 90 days (-$213M, 88 sales vs 1 buy)
Revenue$149.4M
Net Income$63.7M
EPS$0.50
Price Performance
Historical data including institutional events
Company Profile
P
Patrick J. McEnany
CEO & Executive Director
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019.
